A Phase 3 study, CheckMate 8HW, evaluating nivolumab plus ipilimumab compared to nivolumab monotherapy in microsatellite instability-high (MSI-H) metastatic colorectal cancer, was published on January 1, 2025. The trial demonstrated improved outcomes for the combination therapy.
Background
Nivolumab (Opdivo) is an immunotherapy agent. This study investigated its use, both as monotherapy and in combination with ipilimumab, for patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer.
Trial design
The Phase 3 CheckMate 8HW study was a randomised, open-label trial. It evaluated nivolumab plus ipilimumab against nivolumab monotherapy in participants with microsatellite instability-high (MSI-H) metastatic colorectal cancer. The broader study also included an investigator's choice chemotherapy arm.
What this means
The publication of the CheckMate 8HW study in The Lancet indicates that the combination of nivolumab and ipilimumab offers a beneficial treatment option for patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer when compared to nivolumab monotherapy. Clinicians and researchers can refer to the full publication for detailed efficacy and safety data to inform treatment decisions and future research directions.
Source
The information regarding this study publication was sourced from PubMed, a database of biomedical literature. The article, titled "Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 tr", was published on January 1, 2025, and is available via pubmed.ncbi.nlm.nih.gov.